--- title: "LSD therapy biotech Definium sued for alleged trade secret theft" type: "News" locale: "en" url: "https://longbridge.com/en/news/274563320.md" datetime: "2026-02-02T22:05:18.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/274563320.md) - [en](https://longbridge.com/en/news/274563320.md) - [zh-HK](https://longbridge.com/zh-HK/news/274563320.md) --- > Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/274563320.md) | [繁體中文](https://longbridge.com/zh-HK/news/274563320.md) # LSD therapy biotech Definium sued for alleged trade secret theft By Blake Brittain Feb 2 (Reuters) - A clinical-trial provider sued psychedelic therapy developer Definium Therapeutics (DFTX.O) on Monday in Delaware federal court, claiming it stole trade secrets related to LSD trials to share with a upstart rival. Signant Health said in the lawsuit that Definium hired EMA Wellness, which is backed by a Definium executive, to run clinical trials for its LSD treatment and shared confidential Signant information with EMA to “shore up EMA’s nascent capabilities and mask EMA’s inability to perform.” A Definium spokesperson said the company disagrees with the claims and will respond through the legal process. Spokespeople for EMA, which is not a defendant, did not respond to a request for comment. A spokesperson for Signant’s attorneys declined to comment. New York-based Definium, formerly known as MindMed, is developing an LSD therapy to treat severe depression, anxiety and other psychiatric disorders. Definium hired Signant to assist with its Phase 2 clinical LSD trials in 2021. Definium chose EMA to work on its Phase 3 trials in 2024. The lawsuit said the executive running Definium’s procurement process and Phase 3 trial, Todd Solomon, holds a financial stake in EMA and was “secretly working to ensure EMA would win — regardless of merit.” The lawsuit also said that EMA has been working to “knock-off” Signant’s clinical trial platform by hiring former Signant employees, and that Definium and Solomon aided EMA by sharing Signant trade secrets with the company. Signant requested an unspecified amount of monetary damages and a court order blocking Definium from misusing its trade secrets. The case is Signant Health Holding Corp v. Definium Therapeutics Inc, U.S. District Court for the District of Delaware, No. 1:26-cv-00114. For Signant: Patrick Curran, Jared Newton, Eric Wolkoff and Nathan Hamstra of Quinn Emanuel Urquhart & Sullivan; James Boudreau and Joseph Mahady of Reed Smith For Definium: Not yet available ### Related Stocks - [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md) - [Mind Medicine (MindMed) Inc. (MNMD.US)](https://longbridge.com/en/quote/MNMD.US.md) - [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md) - [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md) - [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md) - [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md) - [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/en/quote/IBBQ.US.md) - [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md) - [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md) ## Related News & Research - [Precigen Details Papzimeos Commercial Launch, Hub Growth and J-Code Catalyst at H.C. Wainwright Chat](https://longbridge.com/en/news/281233412.md) - [BUZZ-Caribou rises on FDA's regenerative medicine advanced therapy tag for blood cancer therapy](https://longbridge.com/en/news/281186075.md) - [Io Biotech Inc - Files Voluntary Chapter 7 Bankruptcy Petition On March 31, 2026 - SEC Filing](https://longbridge.com/en/news/281187506.md) - [SeaStar Medical Highlights New Positive QUELIMMUNE Data In Pediatric AKI](https://longbridge.com/en/news/281121555.md) - [MAIA's Phase 2 Trial Shows Eight Lung Cancer Patients Surpassing Two Years Of Survival](https://longbridge.com/en/news/281329946.md)